Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection

2004526 citationsJournal Articlebronze Open Access

Authors

Roy M. Gulick · Cornell University

Heather J. Ribaudo

Cecilia M. Shikuma · University of Hawaiʻi at Mānoa

Stephanie Lustgarten

Kathleen Squires · University of Southern California

William A. Meyer

Edward P. Acosta · University of Alabama at Birmingham

Bruce R. Schackman · Cornell University

Abstract

In this trial of the initial treatment of HIV-1 infection, the triple-nucleoside combination of abacavir, zidovudine, and lamivudine was virologically inferior to a regimen containing efavirenz and two or three nucleosides.

Topics & Keywords

HIV/AIDS drug development and treatment HIV Research and Treatment HIV/AIDS Research and Interventions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 350, Issue 18, pp. 1850-1861

DOI: 10.1056/nejmoa031772

Field-Weighted Citation Impact: 31.66